Drug Approval | May 11, 2024
Strides receives USFDA approval for Sevelamer Carbonate Tablets
Sevelamer Carbonate Tablets approval consolidates the company's position in the Sevelamer segment
Sevelamer Carbonate Tablets approval consolidates the company's position in the Sevelamer segment
Receives 3 final and 2 tentative product approvals thus far in Q1FY25
The approval marks a significant milestone for the American pharmaceutical company in the field of UC
Acquisition to further expand the Alexion, AstraZeneca Rare Disease pipeline beyond complement inhibition
Approval of oral, once-daily VELSIPITY based on favorable safety and efficacy data from the ELEVATE UC Phase 3 trials
Upon approval, XPHOZAH would be the first and only phosphate absorption inhibitor, offering patients a novel mechanism
China has the highest number of clinical trials that were initiated in NAFLD in the APAC region over the past decade.
Sitagliptin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
HealthCare Royalty Partners funding supports the ongoing launch of IBSRELA in the United States
Innate to receive $5M milestone payment from AstraZeneca
Subscribe To Our Newsletter & Stay Updated
